A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH
Public ClinicalTrials.gov record NCT05128942. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of SPR001 (Tildacerfont) in Children Aged 2 to 17 Years With Congenital Adrenal Hyperplasia (CAH)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
An investigation of the safety and efficacy of tildacerfont in participants with CAH.
Study identification
- NCT ID
- NCT05128942
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 67 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 2 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 10, 2021 (Actual)
- Primary completion
- Jan 31, 2025 (Actual)
- Completion
- Jan 31, 2025 (Actual)
- Last update posted
- Dec 24, 2025
2021 – 2025
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Spruce Study Site | Sacramento | California | 95821 | — |
| Spruce Study Site | San Diego | California | 92123 | — |
| Spruce Study Site | Chicago | Illinois | 60611 | — |
| Spruce Study Site | Minneapolis | Minnesota | 55454 | — |
| Spruce Study Site | Buffalo | New York | 14203 | — |
| Spruce Study Site | Providence | Rhode Island | 02903 | — |
| Spruce Study Site | Columbia | South Carolina | 29203 | — |
| Spruce Study Site | Dallas | Texas | 75231 | — |
| Spruce Study Site | Edinburg | Texas | 78539 | — |
| Spruce Study Site | Fort Worth | Texas | 76104 | — |
| Spruce Study Site | Salt Lake City | Utah | 84113 | — |
| Spruce Study Site | Charlottesville | Virginia | 22903 | — |
| Spruce Study Site | Richmond | Virginia | 23284 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05128942, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 24, 2025 · Synced Nov 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05128942 live on ClinicalTrials.gov.